摘要目的 回顾性研究晚期非小细胞肺癌患者放疗前后血清CEA、CYFAR21-1、SCC、CA125的水平变化,探讨血清肿瘤标志物的改变及与放疗近期疗效的关系.方法 常规检查205例经确诊的晚期非小细胞肺癌患者放疗前、后血清CEA、CYFAR21-1、SCC、CA125等肿瘤标志物的水平(应用电化学发光法),同时评估放疗的近期疗效,分析肿瘤标志物的变化及与近期疗效的关系.结果 205例患者放疗后近期有效113例,总有效率为55.1％.此113例患者放疗后血清CEA、CYFAR21-1、SCC、CA125水平均较放疗前发生了明显下降(t=3.224,2.896,3.137,3.219,P＜0.05),其中Ⅲ期及Ⅳ期患者血清肿瘤标志物CEA、CYFAR21-1、SCC、CA125放疗后与放疗前比较,差异均有统计学意义(Ⅲ期:t =2.484,2.445,2.148,2.109,P＜0.05；Ⅳ期:t=2.072,2.857,2.277,2.436,P＜0.05)；而放疗后近期非有效的92例患者中,放疗后血清肿瘤标志物较放疗前明显上升(t=2.224,2.005,2.261,2.545,P＜0.05).放疗后肿瘤标志物降低组的近期疗效明显好于肿瘤标志物升高组,差异有统计学意义(x2=80.001,P＜0.01)结论 血清肿瘤标志物CEA、CYFAR21-1、SCC、CA125水平或可用于晚期非小细胞肺癌患者放疗后的近期疗效评估.

abstractsObjective To investigate the change of the serum levels of CEA,CYFAR21-1,SCC,CA125 in advanced non-small cell lung cancer.patients before and after radiotherapy retrospectively and to explore the relationship between the change of serum tumor markers and the short-term efficacy of radiotherapy.Methods The serum levels of CEA,CYFAR21-1,SCC,CA125 in 205 cases with advanced non-small cell lung cancer were detected (by electro-chemiluminescence immunoassay method)before and after radiotherapy,and the short-term efficacy of radiotherapy was assessed (RECIST 1.1 edition) at the same time.The changes in tumor markers and the short-term efficacy were analyzed.Results Totally 113 patients achieved response of short-term efficacy after radiotherapy,and the effective rate of the short-term efficacy was 55.1％.Among these 113 patients,the serum levels of tumor markers decreased significantly after radiotherapy(t =3.224,2.896,3.137,3.219,P ＜ 0.05).The serum levels of tumor markers in patients with stage Ⅲ and Ⅳ decreased after radiotherapy (t =2.484,2.445,2.148,2.109,P ＜ 0.05 ;t =2.072,2.857,2.277,2.436,P ＜ 0.05).Among 92 patients who did not achieve response of short-term efficacy,the serum level of tumor markers increased significantly after radiotherapy(t=2.224,2.005,2.261,2.545,P ＜ 0.05).For the patient who achieved response of radiotherapy with tumor markers decreased,the short-term efficacy was significantly better than the group of which tumor maker increased (x2 =80.001,P ＜ 0.01).Conclusions The serum levels of CEA,CYFAR21-1,SCC,CA125 can be used for assessment of short-term efficacy after radiotherapy in advanced non-small cell lung cancer patients.